Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aeglea BioTherapeutics In...

    NASDAQ: AGLE · Real-Time Price · USD
    12.01
    0.75 (6.66%)
    At close: Nov 27, 2023, 9:00 PM

    Aeglea BioTherapeutics Statistics

    Share Statistics

    Aeglea BioTherapeutics has 4.05M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 4.05M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 100

    FTD / Avg. Volume

    n/a
    		 0.17%

    Short Selling Information

    The latest short interest is 139.69K, so 3.45% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 139.69K

    Short % of Shares Out

    n/a
    		 3.45%

    Short % of Float

    n/a
    		 3.47%

    Short Ratio (days to cover)

    n/a
    		 4.58

    Valuation Ratios

    The PE ratio is -0.45 and the forward PE ratio is null. Aeglea BioTherapeutics's PEG ratio is 0.71.

    PE Ratio

    n/a
    		 -0.45

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 16.28

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.75

    P/FCF Ratio

    n/a
    		 -0.47

    PEG Ratio

    n/a
    		 0.71
    Financial Ratio History

    Enterprise Valuation

    Aeglea BioTherapeutics has an Enterprise Value (EV) of 7.69M.

    EV / Sales

    n/a
    		 3.3

    EV / EBITDA

    n/a
    		 -0.09

    EV / EBIT

    n/a
    		 -0.1

    EV / FCF

    n/a
    		 -0.1

    Financial Position

    The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 4.25

    Quick Ratio

    n/a
    		 4.25

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.05

    Debt / FCF

    n/a
    		 -0.06

    Interest Coverage

    n/a
    		 -101.29

    Financial Efficiency

    Return on Equity is -166.61% and Return on Invested Capital is -154.08%.

    Return on Equity

    n/a
    		 -166.61%

    Return on Assets

    n/a
    		 -117.81%

    Return on Invested Capital

    n/a
    		 -154.08%

    Revenue Per Employee

    n/a
    		 $33,753.62

    Profits Per Employee

    n/a
    		 $-1,214,710.14

    Employee Count

    n/a
    		 69

    Asset Turnover

    n/a
    		 0.03

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -136K

    Effective Tax Rate

    n/a
    		 0.16%

    Stock Price Statistics

    The stock price has increased by -37.77% in the last 52 weeks. The beta is 2.57, so Aeglea BioTherapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.57

    52-Week Price Change

    n/a
    		 -37.77%

    50-Day Moving Average

    n/a
    		 13.75

    200-Day Moving Average

    n/a
    		 10.26

    Relative Strength Index (RSI)

    n/a
    		 64.73

    Average Volume (20 Days)

    n/a
    		 59,537

    Income Statement

    In the last 12 months, Aeglea BioTherapeutics had revenue of 2.33M and earned -83.81M in profits. Earnings per share was -24.86.

    Revenue

    n/a
    		 2.33M

    Gross Profit

    n/a
    		 2.33M

    Operating Income

    n/a
    		 -84.78M

    Net Income

    n/a
    		 -83.81M

    EBITDA

    n/a
    		 -84.78M

    EBIT

    n/a
    		 -83.11M

    Earnings Per Share (EPS)

    n/a
    		 -24.86
    Full Income Statement

    Balance Sheet

    The company has 34.86M in cash and 4.63M in debt, giving a net cash position of 30.23M.

    Cash & Cash Equivalents

    n/a
    		 34.86M

    Total Debt

    n/a
    		 4.63M

    Net Cash

    n/a
    		 30.23M

    Retained Earnings

    n/a
    		 -425.62M

    Total Assets

    n/a
    		 207.26M

    Working Capital

    n/a
    		 161.08M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -80.14M and capital expenditures -38K, giving a free cash flow of -80.18M.

    Operating Cash Flow

    n/a
    		 -80.14M

    Capital Expenditures

    n/a
    		 -38K

    Free Cash Flow

    n/a
    		 -80.18M

    FCF Per Share

    n/a
    		 -23.78
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -3640.23% and -3598.75%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -3640.23%

    Pretax Margin

    n/a
    		 -3604.59%

    Profit Margin

    n/a
    		 -3598.75%

    EBITDA Margin

    n/a
    		 -3640.23%

    EBIT Margin

    n/a
    		 -3640.23%

    FCF Margin

    n/a
    		 -3442.77%

    Dividends & Yields

    AGLE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -220.99%

    FCF Yield

    n/a
    		 -211.42%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for AGLE.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 8, 2023. It was a backward split with a ratio of 1:25.

    Last Split Date

    n/a
    		 Sep 8, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:25

    Scores

    Altman Z-Score

    n/a
    		 -2.09

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist